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Abstract
Intracerebral malignant brain tumors remain one of the most complex problems of neuro-oncology. Today, promising results 
of the use of targeted drugs have been received, which determine the important diagnostic and predictive value of molecular genetic 
markers of glial and metastatic brain tumors. 
Aim: The study of the prevalence of MGMT (O6-methylguanine-DNA methyltransferase) and PTEN (phosphatase and tensin 
homologue deleted on chromosome 10) gene expression by real time polymerase chain reaction in tumor tissue of gliomas and brain 
metastases.
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Materials and methods: From thirty patients were received tumor material (29 cases of glioma III–IV degree of anaplasia 
and one case of metastatic brain lesion of adenocarcinoma). The normalized expression of MGMT and PTEN genes was determined 
by real-time polymerase chain reaction.
Results: In all 30 (100 %) patients with tumor fragments, we determined normalized expression of MGMT and PTEN 
genes. In most cases, 53 % of the observations (16 out of 30 patients) showed a low normalized expression of MGMT gene 
(<40 c. u.) and a low normalized PTEN expression rate of 73 % (22 out of 30 patients) (<40 c. u.). The average expression level of 
the MGMT gene in the range from 40 to 100 c. u. (6/20 % of patients) was considered prognostic favourable for the response to 
temozolomide chemotherapy.
Conclusions: The study of MGMT gene expression, a chemotherapy marker for temozolomide, indicates a trend toward 
correlation between expression levels and therapeutic efficacy. The study of the expression of the PTEN gene, the blocker of the 
PI3K/AKT signal pathway, indicates a different degree of expression of this enzyme in the tumour samples studied. The predictive 
value of the indicator for target therapy is appropriate in comparison with the EGFR mutation. Further profound analysis of the re-
sults is required with increasing number of sampling and observation period.
Keywords: malignant brain tumors, glioblastoma, MGMT gene, PTEN gene, EGFR, personalized medicine.
DOI: 10.21303/2504-5679.2019.00949
1. Introduction
Intracerebral malignant brain tumors, regardless of their genesis, primary or metastatic, 
remain the most painful and unresolved issue of neuro-oncology [1, 2]. Since the 70s of the last 
century, surgery along with radiotherapy (RT) remains the main methods of treating patients 
with malignant intracerebral tumors. The combination of these two treatments allowed doubling 
the survival rate [3, 4]. The survival of patients with malignant gliomas progressed with the 
development of therapeutic protocols, especially in the introduction of the Stupp protocol of 
chemotherapy (CT) in 2005 in the clinical practice. According to the Stupp protocol, the temo-
zolomide cytotoxic effect (TMZ) is added to the postoperative RT, followed by TMZ CT for six 
cycles. This allowed a two-year overall survival rate to be increased to 26.5 % compared with 
only 10.4 % for post-operative RT in mono-regimen [5]. It is known that TMZ CT in the com-
plex treatment of patients with glioblastoma (GBM) in 39 % of cases increases the average life 
expectancy of some categories of patients up to 24 months [6]. However, TMZ CT is also widely 
known, and is associated, first of all, with resistance to this drug. Despite the fact that TMZ CT 
has been used for more than ten years in the treatment of malignant glial tumors, the causes and 
mechanism of TMZ resistance development are not fully understood today and are the subject of 
scientific research [7, 8].
Independent risk factors associated with less long-term survival in malignant glial tumors 
are age of the patient (≥60 years), non-radical tumour removal, low preoperative functional status 
of the patient (KPS <70), absence of post-operative RT and CT, reduction of postoperative TMZ 
CT (<4 years) [10, 11]. In the case of a more favourable prognosis at the molecular level, the pres-
ence of methylation of the promoter of the O6-methylguanine gene of DNA-methyltransferase 
(MGMT) or the presence of mutations in the isocyte dehydrogenase (IDH) gene (Hartmann et al. 
2013; Reifenberger et al., 2014) may be indicated. It is with the differences in the molecular 
biology of the tumors that the same histotype tumors are different in their response to therapy. 
Therefore, in modern neuro-oncology of special diagnostic and prognostic significance acquire 
molecular genetic markers of tumors, as an essential component of the selection of treatment 
tactics [12].
The development of molecular biology and the orientation towards personalized medicine 
have led to a fundamentally new approach in the treatment of cancer patients with the use of molec-
ular targeting drugs that block the proliferation of tumour cells by selective inhibition of its major 
signalling pathways - ligands, membrane receptors, intracellular proteins, etc. [6].
CT is an important component of the integrated therapy of cancer patients. Heterogeneity 
of tumors of one histotype according to the molecular mechanism of their development and mech-
anisms of chemo-resistance induced to personification of therapy. Today, along with tradition-
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al cytotoxic chemotherapy, targeted therapy is becoming increasingly important. The essence of 
the approach lies in the preliminary study of key genetic mutations that trigger uncontrolled cell 
proliferation and inhibition of apoptosis. Therefore, targeting therapy is based on the blocking of 
processes that are abnormally activated by mutation [13, 14].
When assigning cytostatics, it is important to determine the expression of the corre-
sponding genes of chemoreceptor. Studies are conducted using biopsy or postoperative tumour 
tissue. Thus, the use of an antibacterial CT is based on the need for the prescription of che-
motherapy, either traditional or targeted, from the standpoint of the current level of knowl-
edge about molecular genetic prediction. The deepening of the search for molecular genetic 
markers, which allows predicting the effectiveness of therapy of intracerebral tumors, remains 
relevant in neuro-oncology.
2. Aim of research
The study of the prevalence of MGMT (O6-methylguanine-DNA methyltransferase) and 
PTEN (phosphatase and tensin homologue deleted on chromosome 10) gene expression by real 
time polymerase chain reaction in glioma tumour tissue and brain metastases.
3. Materials and methods 
The research was conducted at the State Institution “Institute of Neurosurgery named af-
ter A.P. Romodanova NAMS of Ukraine” (certificate on quality management is registered in the 
Register of Certification Systems of UkrSEPRO № UA.2.166/0909-15 dated June 10, 2015, valid 
until June 09, 2020), in the Department of Neurobiology (Certificate of Attestation No. PT-221/14 
dated 04.07.2014 till 03.07.2019) which certifies that the department is certified on the basis of 
the Law of Ukraine “On Metrology and Metrological Activity”, meets the criteria for attestation 
of measuring laboratories in accordance with the Rules of Authorization and Certification in the 
State Metrology System. The department is certified for carrying out measurements of the indi-
cators of the objects according to the industry, which is given in the appendix to the certificate 
and is an integral part of it.
All patients included in the study were treated at the State Institution “Institute of Neurosur-
gery named after A.P. Romodanova NAMS of Ukraine”.
The study included patients with different tumour brain lesions: both primary and meta-
static. Surveyed and operated to obtain tumour material for further studies of 30 patients from 
04.2017 to 09.2018: 1 case of anaplastic astrocytomas (AA); 26 cases of GBM IV grade anaplasia, 
of which 22 cases was first-time GBM diagnosis; 3 cases of continued growth (recurrent) GBM; 
1 case of secondary GBM; 1 case of prolonged growth of anaplastic oligodendroglioma (AOG); 
1 case of anaplastic ganglioglioma; 1 case of metastatic adenocarcinoma in the brain. Two of the 
30 patients with GBM, were dropped out of observation, the observations of the remaining 28 pa- 
tients are known.
All patients were informed about the conduct of research and informed consent to their 
implementation. The research was carried out in accordance with the ethical norms adopted by the 
Ukrainian legislation.
Polymerase chain reaction (PCR) method in real time
Material for the study was obtained from fragments of brain tumour tissue extracted during 
surgical intervention. Tissue immediately after sterile removal was treated as follows: the frag-
ments of blood vessels and necrotized fragments were removed, the purified tissue was placed in 
sterile cryotubes and stored in liquid nitrogen at a temperature of – 196 °C until the time of use in 
the experiment.
Isolation of total RNA
The total RNA was isolated from samples of tissues frozen in liquid nitrogen using the 
commercially available PureLink RNA Mini Kit Kit (Applied Biosystems, USA), respectively, 
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the kit instructions. Selection steps consisted of lysis of cells, RNA binding to the membrane, 
purification of RNA and elution. Guanidine isothiocyanate is included in the prevention of degra-
dation of RNA into the lysis and washing buffers. The isolated RNA was placed on ice, checked 
for quality and used immediately for the synthesis of cDNA in the reverse transcription reaction.
Determination of the quality of the isolated RNA
The absorption spectrum of the total RNA solution was roughly estimated by the degree of 
purification of RNA from proteins and guanidine. The ratio of 260 nm/280 nm should be between 
1.9 and 2.1. Samples that had lower or higher values were not included in the experiment. The RNA 
was evaluated by absorbance at 260 nm on a spectrophotometer.
Synthesis of the first chain of cDNA
The cDNA was obtained by kit of Tag Man reverse transcription reagents (Applied Biosys-
tems, USA) using the reverse transcription reaction, respectively, with the kit instructions. The 
reaction was carried out in a volume of 20 μl. OligodT primers were used as primers.
Determination of the level of expression of genes by real-time PCR
The level of expression of MGMT (Hs01037698_m1) and PTEN (Hs02621230_s1) genes was 
analyzed on a real-time PCR fluorescence detection system of the SFX96 Touch (BioRad, USA) 
using Tag Man Universal PCR Master Mix (Applied Biosystems, USA) and Tag Man Gene Expres-
sion Assays (Applied Biosystems, USA) on the following protocol:
Primary denaturation 95 °C – 10 minutes (1 cycle).
Amplification cycle (×40):
– denaturation 95 °C – 15 sec;
– annealing of primers, elongation and fixation of fluorescence signal 60 °C – 1 minute.
All reactions were carried out in separate test tubes. The volume of the reaction mixture 
was 20 μl.
To evaluate the reproducibility of the threshold cycle values, all samples with each pair of 
primers were amplified in double repetition. The difference between the samples was no more than 
0.5 cycle.
Accumulation of amplification products was determined using oligonucleotide samples of 
the TagMan type (probes), complementary to the central portion of the amplified transcript frag-
ment. The FAM is attached to the 5 ‘end of the probe, while the 3’ end carries the MGB shield. 
Upon amplification of the transcript there is a separation of the fluorophore and the absorber and 
the device fixes the fluorescence signal. The oligonucleotide samples that were used to determine 
the expression of the genes studied are shown in Table 1.
To check the absence of amplification of transcript regions of the genes studied on possible 
impurities of genomic DNA in the sample, parallel reactions of amplification of the RNA specimen 
without reverse transcription and cDNA were pre-performed.
Table 1
Nucleotide sequence of fluorescence probes used to determine the level of gene expression
Gene Sequence of the oligonucleotide test
MGMT 5’gcaanccngnccccatcctcatccc 3’
PTEN 5’atgctgcacagaaattttcaatttg3’
GUSB 5’gctactacttgaagatggtgatcgc3’
For the real time PCR method, the gene of glucuronidase GUSB (Hs00939627_m1), 
which belongs to the family of “housekeeping genes”, has been selected as the reference 
Original Research Article:
full paper
(2019), «EUREKA: Health Sciences»
Number 4
29
Medicine and Dentistry
gene for the gene reference MGMT and PTEN, which is characterized by a stable expres-
sion level among various specimens. It is assumed that the change in the amount of its 
cDNA depends only on the influence of additional factors that determine the kinetics of re-
verse transcription. This allows comparing the level of gene expression between different 
samples.
The data analysis was performed at the threshold fluorescence, which is the main criterion 
for evaluating the results. It describes a certain cycle of PCR (Ct), which shows a significant in-
crease in fluorescence compared with the background level and begins the exponential phase of the 
PCR cycle.
The absolute number of copies of the mRNAs of the MGMT and PTEN genes in tumour 
samples was determined using the tenfold dilutions of a fragment of the MGMT gene enclosed 
in the plasmid and constructed on the basis of these data of the standard curve. GeneArt Gene 
Synthesis (Invitrogen, Thermo Fisher Scientific, Germany) was used for this purpose. The 
calculations used the equation of the curve y=–0.3415x+13.275. The difference in the level of 
gene expression between the specimens was evaluated at the normalized number of copies of 
the mRNAs of the MGMT and PTEN genes relative to the number of copies of the housekeep-
ing gene, GUSB.
4. Results
In all 30 (100 %) patients with tumour fragments, we determined normalized expression 
of MGMT and PTEN genes. Table 2 presents the results of the determination of normalized 
expression of MGMT and PTEN genes in the tissue of glial tumour fragments and brain metas-
tases extracted during surgical removal, further adjuvant treatment was traced. In 18 (69 %) 
of 26 patients with GBM, adjuvant radiotherapy (RT) was conducted with concomitant TMZ 
CT. In 14 (54 %) of 26 patients with GBM after completion of postoperative adjuvant RT, TMZ 
CT was performed.
In 16 (53 %) out of 30 examined patients, a low normalized expression of MGMT gene 
(<40 c. u.) was observed. In 6 (20 %) patients, this indicator was in the range of 40 c. u. to 100 c. u. 
The use of TMZ in such cases is considered appropriate and effective, as evidenced by overall 
survival (OS) in the study group of patients (Table 2).
In one case, in a patient with a recurrent GBM (observation No. 27, Table 2), the normalized 
expression of MGMT gene significantly exceeded this indicator and amounted to 2,292.8 c. u. in the 
remaining patients, which is a prognostic negative factor. In this observation, the recurrence-free 
period (RFP) was 18 months, overall survival (OS) was 25 months; the patient died 7 months after 
the onset of relapse.
In the case of secondary GBM (observation № 25, Table 2), the normalized expression 
of the MGMT gene was 10.3 c. u., RT was performed with concomitant TMZ CT, in the subse-
quent treatment of 6 courses of adjuvant TMZ CT. This patient is alive, the observation lasts 
22 months.
In our observation group, in the majority of patients, a low normalized expression of 
the PTEN gene (<40 c. u.) was detected in 22 (73 %) cases. In the remaining 8 (27 %) patients, 
the normalized expression of the PTEN gene exceeded 40 c. u. and ranged from 61.6 c. u. to 
21390.5 c. u. In this case, the correlation between normalized expression of PTEN gene and 
the survival rate of patients, nor the level of normalized expression of MGMT gene has not 
been established. The highest normalized index of PTEN gene expression is 21390.5 c. u. was 
observed in a patient with GBM, which is still alive, is observed for 10 months, data for relapse 
of the tumour has not been received (observation № 19б Table 2). Two patients with GBM 
with high OS 22 months, who are still alive (observation № 1 and 8, Table 2), had the same 
normalized expression of PTEN gene – 0.001 c. u. At the same time, they differed in the level 
of expression of the gene MGMT – 3.1 c. u. and 22.5 c. u. in accordance. Both cases belong to 
a group that has a low normalized expression of MGMT gene (<40 c. u.) and accounts for most 
observations (53 %). 
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Table 2
Expression of MGMT and PTEN genes in the tissue of glial and metastatic brain tumor fragments in 
RT-treated patients using TMZ CT in concomitant and / or adjuvant regimens
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
1 13.07.17 male 56 GBM parieto-occipital/left subtotal 60+TMZ
TMZ  
6 courses 22 12 3.1 0.001
alive (radiosurd-
gery 07/2018)
2 21.06.18 female 48 GBM frontoparietal/left
frac-
tional 60+TMZ
TMZ 
2 courses 11 11 3.3 0.1 alive
3 13.06.18 female 50 GBM fronto-callous/right
frac-
tional 63+TMZ
CCNU 
1 course 11 11 7.3 0.2 alive
4 27.07.17 female 68 GBM two side parietal- callous
frac-
tional – – 9 6 13.5 61.6 died
5 26.06.17 male 39 GBM posterior- 
frontal/right
subtotal 60+TMZ TMZ 3 courses 13 7 17.4 0.1 died
6 04.07.17 female 36 GBM frontal-callous/left
frac-
tional 60+TMZ
TMZ 
3 courses 6 6 17.9 2.0
died as a result 
of pulmonary 
artery thrombo-
sis, death that 
is not related to 
the underlying 
disease
7 08.08.18 male 80 GBM temporoparietal/left subtotal 40+TMZ – 9 3 19.8 0.3 alive
8 27.07.17 male 64 GBM subcortical  
frontal/right
subtotal 60+TMZ – 22 15 22.5 0.001 alive
9 18.12.17 male 56 GBM corpus callosum/left
frac-
tional 60+TMZ
TMZ 
6 courses 18 18 26.30 1.7 alive
10 20.11.17 male 61 GBM frontotemporal/left
frac-
tional – – – – 32.8 229.0
unknown 
(the occupied 
regions of the 
Donetsk region)
11 05.07.17 male 55 GBM frontal medial/right subtotal 60+TMZ
CCNU 5 
courses 22 22 39.6 1.3 alive
12 03.04.17 male 37 GBM frontal medial 
occipital/right
subtotal 60+TMZ TMZ 6 courses 11 8 40.6 0.5 died
13 30.05.18 male 43 GBM temporal/right total 60+TMZ TMZ 3 courses 12 12 48.6 0.2 alive
14 13.04.17 male 53 GBM frontotemporal/right subtotal 60+TMZ
TMZ 
5 courses 25 12 49.8 0.4 alive
15 12.04.17 male 40 GBM frontal/right
subtotal- 
frac-
tional
60+TMZ
TMZ 
6 courses 25 17 70.4 1.45 alive
16 18.12.17 male 47 GBM temporal/right total 60–TMZ TMZ 3 courses 17 17 89.8 259.7 alive
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
17 20.06.18 male 70 GBM frontal medial/right subtotal 60+TMZ
TMZ 
2 courses 11 11 90.5 24.6 alive
18 12.12.17 female 37 GBM frontal/left total – – – – 105.9 2747 unknown
19 30.07.18 female 49 GBM frontal medial/right subtotal 60+TMZ – 10 10 118.3 21390.5 alive
20 27.11.17 male 67 GBM frontotemporal 
parietal/right
subtotal 60–TMZ – 18 5 125.6 651.6 alive
21 23.04.18 female 62 GBM partial temporal 
subcortical/left
subtotal 60+TMZ TMZ  4 courses 13 13 192.6 13.1 alive
22 27.04.17 female 66 GBM temple/right total 60+TMZ TMZ 3 courses 13 12 251.6 2.7 died
23 13.06.18 female 65
GBM with 
oligoden-
droglial 
component
temporal  
subcortical/left
frac-
tional – – – – 9.0 0.8
died in the 
postoperative 
period, RT and 
ACT were not 
conducted
24 29.06.17 male 52 АА frontotemporal/right subtotal – – – – 125.0 8.6
died in the 
postoperative 
period, RT and 
ACT were not 
conducted
25 24.07.17 female 50 secondary GBM frontal/right total 60+TMZ
TMZ 
6 courses 22 22 10.3 0.2 alive
26 11.05.18* male 52
cont. 
growth. 
GBM
temple/right total – – 5** 5** 20.5 390.8 died
27 26.02.18* female 58
cont. 
growth. 
GBM
temple/left
frac-
tional – – 7
** 7** 2292.8 164.6
died (RFP after 
the first opera-
tion 18 months)
28 02.04.18* female 42
cont. 
growth. 
(AOD)
temple/right total 60–TMZ РСV 13 13 205.1 9.6 alive
29 30.05.18 female 62
Adeno-
carcinoma 
metastasis
sincipital/right total 60–TMZ CCNU 12 12 5.3 0.001 alive
30 14.09.18 female 43
Anaplastic 
gangliogli-
oma
parietomedial/
right
frac-
tional 60–TMZ РСV 8 8 6.8 0.1 alive
Note: * – date of surgery for tumour recurrence (re-operation); ** – survival in the post recessional period; MGMT (O6-meth-
ylguanine-DNA-methyltransferase); PTEN (phosphatase and tensin homologue deleted on chromosome 10); RT (radiotherapy); 
CT (chemotherapy); TMZ (temozolomide); OS (overall survival); RFP (recurrence-free period); АCT (adjuvant chemotherapy); 
CCNU (lombustine); Dose, Gy – total dose of RT in Gray
5. Discussion
As a result of our work, the prevalence of expression of MGMT and PTEN genes by re-
al-time PCR in glandular tumor tissue and brain metastases has been studied. In all 30 (100 %) 
patients with tumor fragments, we determined normalized expression of MGMT and PTEN genes. 
In most cases, 53 % of the observations (16 out of 30 patients) showed a low normalized expression 
of MGMT gene (<40 c. u.) and a low normalized expression of PTEN gene – 73 % (22 out of 30 
patients) (<40 c. u.). In this case, correlation of normalized expression of PTEN gene with survival 
of patients and level of normalized expression of MGMT gene has not been established. In 6 (20 %) 
patients, normalized expression of the gene MGMT varied in the range of 40 c. u. up to 100 c. u. 
Such cases were considered prognostic favorable for the response to TMZ CT, which is confirmed 
Continuation of Table 2
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by survival rates in the study group. Our results indicate a correlation between the level of expres-
sion of the MGMT gene and the efficacy of TMZ CT.
Unfortunately, in our work, due to the small sample size, we were unable to analyze the sta-
tistical significance of the results obtained, as well as to estimate the predictive significance of the 
expressions of the MGMT gene and the PTEN gene. This is a weak link in our study and requires 
further analysis of the results with an increase in the number of samples and the period of observation.
It would also be interesting to investigate the mutations in the EGFR gene (epidermal growth 
factor receptor, ErbB-1) in the samples presented, the correlation of this mutation with the level of 
expression of the PTEN gene, and to analyze their prognostic value for assessing the effectiveness 
of EGFR targeting therapy in neuro-oncology patients.
Thus, there is a need to continue such a study, deepen the analysis and implement the results 
in clinical practice. 
The subject of our research is relevant in neuro-oncology and corresponds to the demands 
of modern scientific research. To date, molecular biology has identified several genetic loci in the 
human genome, whose functioning determines the effectiveness of antitumor effects of CT and 
RT. Deepening understanding of the molecular-biological properties of brain tumors leads to the 
expansion of therapeutic options, primarily targeted therapy. In recent years, the number of publi-
cations devoted precisely to the clinical aspects of molecular biology has increased.
Yes, Brandes A.A. and co-authors (2017) studied the role of MGMT methylation status at 
various stages of GBM pathomorphism. It has been determined that one of the key factors to be taken 
into account when treating malignant glioma is the functioning of the gene of the reparative enzyme 
MGMT. The gene of the reagent enzyme, MGMT, rapidly resumes damage to the DNA of cells by 
glioma (and all other proliferating cells of the patient’s body) after the effects of the alkylating agent. 
The presence of MGMT gene expression depends on the functioning of other genes (for example, 
DNA gene promoter of methylation), some gene ensembles that affect apoptotic processes, etc. [15].
Published in 2018, the work of Nguyen, H. S., and co-authors is devoted to the study of mo-
lecular markers of resistant GBM and ways to overcome therapeutic resistance [16]. The authors 
emphasize that the study of expression of the gene MGMT, a product that reduces the effectiveness 
of alkylating cytostatics, is necessary for the administration of TMZ CT.
The main modern trend in neuro-oncology is the person-oriented approach in the appoint-
ment of antibacterial chemotherapies. First of all, this is due to the heterogeneity of the tumors of 
one histotype by the molecular mechanism of their development and mechanisms of chemo-resis-
tance. The basis of targeted therapy, unlike traditional cytotoxic chemotherapy, is the blocking of 
processes that are abnormally activated due to mutations.
In the cells of many tumors, EGFR abnormal receptors are detected as a consequence of the 
mutation of this gene. In cells with mutation activation of the signaling pathway of EGFR occurs, which, 
in turn, initiates the processes of malignant transformation in most tumors. The presence of gene mu-
tations in the EGFR allows the selection of a group of patients who may have a positive response to the 
inhibitor of the tyrosine kinase of the epidermal factor receptor. The work of Kwatra M. M. and co-au-
thors (2017) is devoted to the analysis of EGFR targeting GBM therapy [17]. The EGFR transmembrane 
receptor binds to extracellular ligands belongs to the family of transmembrane receptors: EGFR (ErbB-1), 
HER2 / c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4), the intracellular part of which exhibits ty-
rosine kinase activity. The amplification of the EGFR gene is found at 60 % GBM, in the half of GBM, 
hyperfragmentation of EGFR is observed. Studies with blockers and antibodies to EGFR (Erlotinib, 
Gefitinib, Nimotuzumab) are currently ongoing and require more advanced scientific research [17, 18].
Eskilsson E. and co-authors in 2018 presented a work concerned with EGFR heterogeneity 
GBM and therapeutic aspects of this problem. Such studies provide an opportunity for the proper 
administration of a specific inhibitor of tyrosine kinase - erlotinib and hefitinib [19].
Elsamadicy A. A. and co-authors (2017) show positive results of the use of the EGFR vIII 
(Rindopepimut (CDX-110)) protein in the vaccine against line I therapy in patients who did not 
receive TMZ. At this time, a separate type of EGFR-EGFR variation-EGFR version III mutation, 
which occurs in 20 % GBM, is highlighted. It should be emphasized that the best results in this 
study were obtained in patients with unmethylated MGMT [20].
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Recent studies have shown the expediency of molecular genetic prediction of the effective-
ness of target-therapy of the brain tumors with the detection of mutations in the gene of EGFR 
(abnormal splicing and mutations in 18–21 exons, only 19 mutations) and expression of the PTEN 
gene. Recent work has been published that thoroughly the role of the PTEN protein in neuro-onco-
genesis has been determined. In articles by Kang Y. J. and Benitez J. A., the molecular-biological 
significance of the PTEN protein and mutations in the PTEN gene [21, 22] is analyzed in detail. 
The PTEN protein encoded by the PTEN gene plays a role in the regulation of the cell cycle, is a 
tumor suppressor and functions as phosphatase. The main function of PTEN is the inhibition of 
the signal path controlled by phosphoinositol-3-kinase - one of the main pathways responsible for 
proliferation and cell survival. PTEN is part of a signaling pathway that stops cell division and 
induces apoptosis. Apoptosis is that of uncontrolled cell growth and progression of the oncological 
process. With malignant transformation, the cells accumulate mutations that ensure the progression 
of tumors. Mutations in the PTEN gene lead to the development of many tumors. The genetic in-
activation of PTEN is indicated for GBM, uterine cancer, prostate cancer, and a decrease in PTEN 
activity is observed in lung cancer, breast cancer, and others.
In 2014, a meta-analysis was conducted on the study of the PTEN gene and its predictive 
value in gliomas [14]. It has been shown that the PTEN gene study is needed to evaluate the ef-
ficacy of EGFR targeting therapy, which is one of the few negative PI3K/AKT/mTOR signaling 
pathways and plays an important role in cellular proliferation, apoptosis and tumor invasion regu-
lation. The sensitivity to therapy of brain tumors with EGFR inhibitors is significantly higher when 
coexpressed by the EGFRvIII oncogene and the PTEN tumor suppressor. In this case, the loss or 
mutations of the PTEN gene make the tumor resistant to EGFR inhibitors, as the PI3K/AKT/mTOR 
signaling pathway is not excluded. It has been established that a decrease in PTEN expression is a 
negative predictive marker for GBM survival, as well as a therapy response marker.
All this confirms the relevance of our research and the feasibility of further scientific re-
search, aimed at studying the molecular genetic features of intracerebral tumors.
The authors report that there is no conflict of interest.
6. Conclusions
1. A study of MGMT gene expression, a marker of temozolomide chemotherapy sensitiv-
ity, indicates a trend towards correlation between expression levels and therapeutic efficacy. To 
determine statistically significant prognostic effects and informativeness of MGMT expression, 
it is necessary to expand the statistical sample and further studies with a larger number and ob-
servation period.
2. A study of the expression of the PTEN gene, the PI3K/AKT signalling pathway blocker, 
indicates a different degree of expression of this enzyme in the tumour samples studied. The pre-
dictive value of this indicator for targeting chemotherapy is possible in comparison with the EGFR 
mutation in these tumour tissue samples.
3. The study of molecular biological characteristics of intracerebral tumors and the imple-
mentation of these data in clinical practice provides the opportunity to develop more effective 
therapeutic protocols based on a personified approach to the treatment of neuro-oncology patients.
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